English

Navamedic: Q1 2006 presentation at Felix 3 May at 08:00

Report this content
Navamedic ASA invites to a presentation of the company's Q1 2006 results on 3 May 2006. The presentation will take place at Felix Conference Centre at Aker Brygge, Bryggetorget 3, 0114 Oslo, and will start at 08:00 a.m. Participants are requested to register at firma@navamedic.com or by calling +47 67 11 25 40.
(Lysaker, Norway, 28 April, 2006) The company's financial calendar for 2006 runs as follows:


3 May 2006: Q1 2006 results, presentation at Felix Conference Center
23 August 2006: Q2 2006 results, presentation at Felix Conference Center
25 October 2006: Q3 2006 results, presentation at Felix Conference Center
13 February 2007: Q4 2006 results, presentation at Felix Conference Center


For further information, please contact:


CEO Øyvind S. Brekke, Navamedic
E-mail: oyvind.brekke@navamedic.com
Office: +47 67 11 25 40, Mobile: +47 91 19 81 64


CFO Jon W. Ringvold, Navamedic
E-mail: jon.ringvold@navamedic.com
Office: +47 67 11 25 44 Mobile: +47 99 15 85 34


About Navamedic ASA:
Navamedic is a Norwegian speciality pharmaceutical company focusing on the development and production of glucosamine HCl (hydrochloride) based medicines. Glucosamine is a generic active ingredient which relieves pain and improves function in patients with mild to moderate osteoarthritis. The product has a favourable safety profile. Osteoarthritis is a chronic disease which affects a large and growing share of the world's population. Navamedic aims to become a leading company in the glucosamine industry, with a competitive advantage in proprietary production technology. The company's products will be sold through a network of sales, marketing and distribution partners. Navamedic's product Glucomed® has been approved as a medicine against osteoarthritis in 20 European countries. The product was launched in Sweden in December 2005, and Navamedic prepares product launches in further European countries in 2006.

Subscribe